2017 American Transplant Congress » Poster Session B: Kidney Immunosuppression: Induction Therapy

6:00pm-7:00pm

A Comparison of Medical Costs Among ABO-Compatible, -Incompatible, and -Minor Mismatched Living Kidney Transplantation: A Single-Center Study.

D. Fujimori, M. Okumi, K. Ungami, H. Ishida, K. Tanabe.

6:00pm-7:00pm

Alemtuzumab Induction Is Safe, and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients.

A. Seitz,¹ M. Robb,² N. Ahmad,¹ A. McLean,³ D. Taube,³ R. Johnson,² R. Baker.¹

6:00pm-7:00pm

Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction.

Y. Takada, K. Hotta, D. Iwami, H. Higuchi, T. Hirose, H. Sasaki, N. Shinohara.

6:00pm-7:00pm

Clinical and Pathologic Characteristics of Acute Rejection After Alemtuzumab Induction in Kidney Transplant Recipients.

P. Zhang,¹ H. Amer,² C. Schinstock,² M. Alexander,¹ F. Cosio,² M. Stegall,³ L. Cornell.¹

6:00pm-7:00pm

Course of Donor Specific Anti-HLA Antibodies After Induction Therapy with Rituximab in Renal Transplantation.

M. Baas,¹ W. Allebes,² M. van den Hoogen,³ I. Joosten,² L. Hilbrands.¹

6:00pm-7:00pm

De Novo Malignancy Occurrence After Kidney Transplantation in HLA-Sensitized Patients Treated with B-Cell Targeting Therapy.

L. Couzi,^1,2,3 P. Davis,¹ J. Visentin,^1,2,3 B. Taton,¹ G. Guidicelli,¹ H. Kaminski,^1,2,3 P. Merville,^1,2,3 T. Bachelet.⁴

6:00pm-7:00pm

Does Choice of Induction Agent Affect Outcomes in Kidney Transplants from Deceased Donors with Acute Kidney Injury and Prolonged Cold Ischemia Time?

G. Dube, S. Mohan, M. Chiles.

6:00pm-7:00pm

Early Rejection in the Elderly: Is It Predictable?

J. Clark, T. Sparkes, B. Masters, S. Jonchhe, A. Haririan, B. Thomas, B. Ravichandran.

6:00pm-7:00pm

Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.

O. Marion,¹ A. Del Bello,¹ I. Ferrandiz,¹ L. Esposito,¹ N. Congy,² A.-L. Hebral,¹ N. Kamar.¹

6:00pm-7:00pm

Induction Immunotherapy in ECD and DGF Kidneys: Does ECD Equal Diminishing Induction Returns?

M. Barrett, A. Smith, K. Woodside, R. Sung.

6:00pm-7:00pm

Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal.

S. Gabardi.

6:00pm-7:00pm

Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.

J. Lee, E. Liu, M. Aull, S. Kapur.

6:00pm-7:00pm

Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results.

K. Korneffel, B. Gehring, G. Mitro, O. Aboderin, S. Makkar, W. Han, M. Rees, J. Ortiz.

6:00pm-7:00pm

Long-Term Persistence of Anti-HLA Antibodies in Renal Trasplant Recipients: Risk Factors and Impact on Clinical Course.

I. Perez-Flores,¹ J. Santiago,² B. Rodriguez-Cubillo,¹ M. Moreno De La Higuera,¹ V. Lopez De La Manzanara,¹ J. Bautista-Cañas,¹ N. Calvo Romero,¹ A. Shabaka,¹ E. Urcelay,² A. Sanchez-Fructuoso.¹

6:00pm-7:00pm

National Variation in US Kidney Transplant Induction Therapy.

V. Dharnidharka,¹ A. Naik,² T. Alhamad,¹ D. Axelrod,³ M. Schnitzler,^4,6 Z. Zhang,⁴ S. Bae,⁵ D. Brennan,¹ D. Segev,⁵ H. Randall,⁴ M. Nazzal,⁴ R. Ouseph,⁴ B. Kasiske,⁶ K. Lentine.⁴

6:00pm-7:00pm

Optimal Induction Therapy for Kidney Transplantation in Previous Heart Transplant Recipients: Analysis of OPTN/UNOS Registry.

M. Sampaio, S. Hussain, B. Chopra, K. Sureshkumar.

6:00pm-7:00pm

Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-Free and CNI Minimization Maintenance Immunosuppressive Regimen.

T. Sandes-Freitas, J. Junqueira, Jr, C. Girão, M. Oliveira, R. Esmeraldo.

6:00pm-7:00pm

Renal Transplant Patient Outcomes Following Plasmapheresis, Thymoglobulin, and Rituximab Induction for High Risk DSA Positive Recipients.

E. Lessmann,¹ M. Moaddab,¹ M. Manson,¹ A. Ram,² R. Kerman,² P. Jindra.²

6:00pm-7:00pm

Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients: A Mate Kidney Analysis.

M. Sampaio, K. Sureshkumar.

6:00pm-7:00pm

The Impact of Induction Therapy on Delayed Graft Function Following Kidney Transplantation in Mated Kidneys.

T. Butler, N. Hayde.

6:00pm-7:00pm

Understanding the Role of Induction Agents in Older versus Younger Kidney Transplant Recipients.

Q. Huang, F. Ammary, M. McAdams-DeMarco, D. Segev.

6:00pm-7:00pm

Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.

M. Marron-Wojewodzki,¹ I. Szwarc,¹ C. Rene,² J.-F. Eliaou,² G. Mourad,¹ M. Le Quintrec.^1,3